Brands
The secret sauce to Royal Enfield’s success in India
MUMBAI: Royal Enfield or RE as it is popularly known has been one of the secretive brands that have forever been tight-lipped; never wanting to talk about its advertising, structure or business model. But it was a rare sight at Zee Melt 2018 where Royal Enfield president Rudratej Singh engaged with the audience for the first time to talk about why the brand stays away from advertising and its brand philosophy.
First produced in 1901, Royal Enfield is the oldest motorcycle brand in the world still in production, with the Bullet model enjoying the longest motorcycle production run of all time.
Singh kicked off his session with a short film that showcased how its consumers are not just consumers but rather a community who believe in the true spirit of riding. “We are a bunch of riders, for riders. We do not sell motorcycles but what your motorcycle can do in terms of experience,” he said.
Singh thinks that the entire team at Royal Enfield is a bunch of storytellers trapped in an automative company and they like to express themselves via its motorcycles. Although RE is the world’s fastest growing automative company today, Singh modestly calls it a small organism that is trying to become an organisation.
While other brands spend millions on advertisement and production, RE likes to keep it in-house and authentic. “Most of the communication and films for Royal Enfield are produced and directed in-house which saves us a lot of money rather than having an agency do it for us which would charge us nothing less than a few lakhs,” he says.
While everyone’s guessing the secret sauce of RE’s success, it is simply a balance between keeping it aspirational and accessible. The former in being authentic for what the brand stands for and the latter in terms of cost, cost of ownership, availability and usability.
Although the company sells motorcycles, it believes that it can motivate people to undertake travelling, something that RE owners definitely love to do, and self discover.
RE doesn’t believe in being omnipresent. For it, context matters. Singh said, “We would rather be visible on contextual events and gathering which are relevant to us rather than being present everywhere.” Royal Enfield spends a major chunk of its time and money on creating events, experiences and products. Singh said that the company has rejected several associations where it could have had front page coverage but did not do that since it was not relevant to them and it doesn’t believe in “that kind of marketing”.
The core of RE is to build meaningful relationships with its customers. This is done by sending frequent messages about joining its rides, attending events, being a part of the community and so on. This, in turn, has helped the brand in gaining consumer trust which is a huge asset for the motorcycle company.
Although the company has always refrained from television commercials and major advertisements on any platform, it has always been dragged into controversy, if not by its own will then by its competitor’s statements and ads. On this, Singh said, “We always knew that we are here to expand our own market and not snatch somebody else’s market. We analyse ourselves rather than nitpicking on other companies in the segment.”
Automation industry is all about product-led innovation and coming up with new products and launches but RE thinks of itself as a brand-led company which can do various things without being product led since brands tend to have a larger impact. Calling the company a zero GRP brand, Singh stated the reason for it being this way was because it has no money or time left and it becomes inauthentic the minute it tries to reach a large number of audience with similar communication. He said that a lot of focus for advertisers and marketers today is perennially on marketing and advertising. What you see now is only the lag of what has been happening in the industry for 15 years and the industry needs to buck up and do something about it. Marketers are trained to go for reach and frequency but the result of this approach is that people stop caring about the brand after a point of time because every communication they see around them is the same.
“We believe in getting across our message with minimum content and minimum cost. We don’t want to blast the internet and television spots with visibility. We always struggle with having little communication with a large group of audience at RE but we are okay with that,” he concluded.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
